Latest News

UHN Spin-off Thornhill Medical to deliver mobile ventilator systems to Government of Canada and Government of Ontario

March 31, 2020 /in Latest News

 

As announced today by Canadian Prime Minister Justin Trudeau and Federal Minister of Innovation, Science and Industry Navdeep Bains Thornhill Medical, a leading innovator in medical technologies, has agreed to produce and deliver 500 mobile compact ventilator systems as part of Canada’s response to fight COVID-19.

Today’s announcement comes on the heels of an agreement signed with the Government of Ontario and Thornhill Medical to produce and supply several of its compact, portable ICU units for use across the province. Thornhill Medical’s MOVES® SLC™ is already in use around the world and is produced at the company’s own manufacturing facility in Toronto.

Following the recent signing of a letter of intent by the Government of Canada, Thornhill Medical moved immediately to scale up its production plans and expand its...

Read More

Support UHN in the COVID 19 Pandemic

March 26, 2020 /in Latest News

For those looking for a way to help during this uncertain time, Toronto General & Western Hospital Foundation has established an emergency #COVID19 fund to support the highest-priority needs of UHN's Toronto General and Toronto Western hospitals during this pandemic. The funds raised by this emergency COVID-19 fund will support the most urgent needs of UHN's Toronto General and Toronto Western hospitals during this pandemic.  Please visit their website for more information. 

UHN researchers studying if popular drug protects healthcare workers from COVID-19

March 25, 2020 /in Latest News

UHN researchers are leading a study to see if a drug which has been licensed for decades to ward off malaria and treat lupus and rheumatoid arthritis can protect healthcare workers from COVID-19.

Dr. Kevin Kain, a researcher at the Toronto General Hospital (TGH) Research Institute, and Dr. Megan Landes, an Emergency Department (ED) physician at TGH, are co-Principal Investigators in the study, which will investigate whether a safe derivative of chloroquine – called hydroxychloroquine – can protect essential frontline staff in the ED and Intensive Care Unit (ICU) from COVID-19.

Called the HEalth Care Worker pROphylaxis (HEROs) Trial, it's one of the world's first randomized controlled studies of hydroxychloroquine to prevent coronavirus infections in ED and ICU staff. An interim analysis of results could come by the...

Read More

UHN Spin-off Thornhill Medical joining the fight against COVID-19

March 24, 2020 /in Latest News

 

Thornhill Medical, a company that got its start at UHN, manufactures a portable ventilator that can help Canadian patients with COVID-19.

The portable intensive care unit, operated by battery power, has a ventilator, oxygen concentrator and can perform vital signs monitoring, among other features.

Originally developed to treat members of the military who had been critically injured and were in need of transport, the technology will now be used to assist patients who need life support due to the current global pandemic, says Dr. Joe Fisher, an anesthesiologist at Toronto General Hospital and a professor in the department of anesthesiology and pain medicine in the Faculty of Medicine at the University of Toronto (U of T).

Dr. Fisher is co-founder of Thornhill Medical, which manufactures the device. He is a Director of the company, as is Dr. Ludwik Fedorko...

Read More

TDC is Hiring! Licensing and Commercialization Associate – Business Intelligence

March 12, 2020 /in Latest News

 

TDC is recruiting a Licensing and Commercialization Associate – Business Intelligence, who will work collaboratively as part of the UHN TDC team by conducting financial valuations, market analyses and commercial support of UHN inventions and technologies. This is a key role within TDC to ensure we are receiving ‘fair value’ for our technologies and understanding what the commercial potential of those technologies is.

For full details and to apply, click here.

UHN's Toronto General Hospital #4 in the World in Newsweek's World's Best Hospitals 2020

March 06, 2020 /in Latest News

Toronto General Hospital number four in the world

For the second year in a row, Toronto General Hospital (TGH) has been ranked one of the world's best hospitals in a global ranking. TGH is ranked number four – up three spots from last year's inaugural listing – and is again the only Canadian hospital in the top 10.

TGH is cited for its world-leading Sprott Department of Surgery, Peter Munk Cardiac Centre and Soham & Shaila Ajmera Family Transplant Centre. TGH's excellence in the fields of endocrinology, autoimmunology and diabetes, its work to provide access to high-quality care to patients in remote communities, and a strong strategic plan were also contributing factors.

The ranking, managed by a global market research company in partnership with Newsweek magazine, rated more than 1,000 healthcare institutions. ...

Read More

TDC is Hiring! Commercial Agreements Specialist

March 05, 2020 /in Latest News

 

See full details and apply online here!

 

University Health Network (UHN) is looking for an experienced professional to fill the key role of Commercial Agreements Specialist in our Technology Development and Commercialization Department (TDC).

UHN is Canada’s largest research hospital, consisting of six research institutes located within the hospital system comprised of Princess Margaret, Toronto General, Toronto Rehabilitation and Toronto Western with all affiliated with the University of Toronto. UHN has a proud history of innovative research and important discovery, and is the largest research hospital in...

Read More

UHN's Dr. Ren-Ke Li's New conductive biomaterial helps damaged hearts beat normally by reconnecting healthy tissue

March 04, 2020 /in Latest News

Closing the Gap

New conductive biomaterial helps damaged hearts beat normally by reconnecting healthy tissue.

 

Heart muscle cells known as cardiomyocytes (illustrated above) are responsible for heart contractions. They are arranged side-to-side and are tightly connected to each other.

Like the arms of spectators rising and falling in unison during a ‘stadium wave’ at a game, the muscles in the heart contract in unison across the heart. This concerted contraction efficiently pumps blood throughout the body.

However, after a heart attack, regions of the heart can become damaged and lose their ability to contract. “When a heart attack occurs, muscle cells known as...

Read More

A therapy based on research conducted at UHN now in clinical trials for COVID-19

March 02, 2020 /in Latest News

A therapeutic agent arising from research conducted in 2002 by Drs. Josef Penninger and Michael Crackower at UHN's Princess Margaret Hospital is now being tested for effectiveness against COVID-19.

See details:

https://nationalpost.com/news/ubc-research-helps-fuel-potential-covid-19-treatment/wcm/a3b6d1d2-0548-4ba6-84e9-3606917d167a

https://www.cbc.ca/news/canada/british-columbia/ubc-researcher-treatment-covid19-1.5477607

 

UHN Spin-off NoNO Inc. Reports Groundbreaking Results in Phase 3 Acute Ischemic Stroke Study

February 21, 2020 /in Latest News

PRESS RELEASE

NoNO Inc. Reports Groundbreaking Results from the Phase 3 ESCAPE-NA1 Study of the Peptide, Nerinetide, in Acute Ischemic Stroke

The novel peptide nerinetide, without prior administration of alteplase, improved functional outcome, reduced mortality and reduced infarct volume among acute ischemic stroke patients

Data presented at the plenary session of the International Stroke Conference 2020 and simultaneously published online in The Lancet

TORONTO, Feb. 20, 2020 (GLOBE NEWSWIRE) — NoNO Inc., a privately-held biotechnology company, today reported results from the pivotal Phase 3 ESCAPE-NA1 study, a multicenter, randomized, double-blinded, placebo-controlled, parallel group,...

Read More

Come learn about Novela’s unique Open Source Wireless Neuromodulation Research Kit at UHN's CRANIA Industry Partnership Day

February 12, 2020 /in Latest News

CRANIA, Novela Neurotech and Hahn Schickard join hands to accelerate the translation of Novela’s neuromodulation research kit

TORONTO, ON — February, 2020 – CRANIACenteR for Advancing Neurotechnological Innovation to Application, a world-class centre for R&D, application and commercialization of neuromodulation innovations and interventions, championed by the University Health Network (UHN), Canada’s largest research hospital, and the ...

Read More

UHN Spin-off Bridge7 Oncology Wins Prestigious FACIT's Falcons' Fortunes Pitch Competition

February 06, 2020 /in Latest News

FACIT announces Artificial Intelligence pitch as Winner of 2020 Falcons' Fortunes on World Cancer Day

Annual cancer-focused pitch competition showcases Ontario's emerging entrepreneurs and FACIT's commitment to drive local value from intellectual property

TORONTO, ON (February 5, 2020) – In front of another at-capacity, packed house of scientists, innovation experts and community stakeholders, FACIT crowned the newest winner of its annual Falcons’ Fortunes pitch competition. The winning pitch was delivered by Mr. Meir Dick of Bridge7 Oncology. This local start-up is scaling clinical expertise with AI to automate and improve the efficiency,...

Read More

UHN, Canada’s largest research hospital, launches another company based on drugs discovered and developed at Princess Margaret

January 14, 2020 /in Latest News

TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets

Industry Veteran Rachel W. Humphrey, M.D., Head of R&D at TIO Discovery, appointed as Board Member and Chief Medical Officer of Treadwell Therapeutics

January 13, 2020 08:05 AM Eastern Standard Time

NEW YORK--(BUSINESS WIRE)--TIO Bioventures, an emerging life science venture creation fund with a mission to build companies with innovative anti-cancer therapies, today announced the launch of Treadwell Therapeutics, a clinical-stage oncology company exploiting cancer cells’ vulnerabilities to develop first-in-class and best-in-class small molecules to address unmet needs in patients with cancer. Treadwell, one of TIO Bioventures family...

Read More

TDC is Hiring! Administrative Assistant II, Research Agreement & Finance Support

January 10, 2020 /in Latest News

Join TDC! The Administrative Assistant II, Research Agreement & Finance Support, will have an important role in TDC operations, ensuring that the numerous Material Transfer Agreements (MTAs),certain other agreements, as well as invoices and revenue distributions which pass in and out of UHN are processed quickly, accurately, and documented appropriately. 

See full details and apply online HERE

 

 

Behind the Breakthrough Podcast Episode 11 - Beating back Alzheimer’s, one poem at a time, with Dr. Donald Weaver

December 17, 2019 /in Latest News

Air Date: December 17, 2019 | Length: 37:14

In the final episode of Behind the Breakthrough, we hear from Dr. Donald Weaver, director of the Krembil Research Institute. Dr. Weaver talks about his groundbreaking research into Alzheimer’s disease, and explains how drug research works and the challenges of getting to a clinical trial. He also tells us why his response to questions of “What next?” is a cheery “More failure!,” the purpose of his weekly story-telling in team meetings, and talks about his poetry career.

Get this episode:​

...

Read More

Behind the Breakthrough Podcast Episode 9 - Pioneering research by UHN’s Dr. Kristin Musselman is designed to get spinal cord injured patients mobile

December 06, 2019 /in Latest News

Air Date: December 3, 2019 | Length: 30:22

Dr. Kristin Musselman is a pioneer in research designed to get patients with partial spinal cord injury up and walking again. She joins UHN’s Behind the Breakthrough podcast to talk about her latest research, how it relies heavily on patient input, and the satisfaction of seeing those same patients try new strategies to regain mobility and maintain their balance.

Get this episode:​

...

Read More

UHN Spin-off MolecuLight Receives FDA 510(k) Clearance for its i:X® Handheld Fluorescence Imaging Device for Wound Management

December 05, 2019 /in Latest News

New FDA Approval Extends Label to Including the i:X’s Detection of Bacteria and Digital Wound Measurement

TORONTO, Canada – (December 5, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of fluorescence in wounds, has received FDA 510(k) clearance for its i:X® handheld fluorescence imaging device for use in the detection of wounds containing bacteria. This FDA 510(k) clearance is an expansion of the original de novo clearance for the MolecuLight i:X platform, granted on August 14, 2018. The MolecuLight i:X enables real time point-of-...

Read More

Behind the Breakthrough Podcast Episode 8 - Reversing blindness and the serendipity of science, with Dr. Valerie Wallace

December 02, 2019 /in Latest News

Air Date: November 26, 2019 | Length: 35:04

Dr. Valerie Wallace is on a mission to reverse blindness. The award-winning senior scientist and co-director of the Donald K. Johnson Eye Institute at UHN’s Krembil Research Institute sits down with Behind the Breakthrough to discuss the serendipity of science, the curiosity that drives her and the changing landscape of women in STEM.

Get this episode:​

...

Read More

Behind the Breakthrough Podcast Episode 7 – Repairing broken hearts with stem cells, with Dr. Michael Laflamme

December 02, 2019 /in Latest News

Air Date: November 19, 2019 | Length: 28:22

In this episode of Behind the Breakthrough, we hear from cardiac pathologist and award-winning principal investigator at the McEwen Stem Cell Institute Dr. Michael Laflamme. His mission: to restore the function of injured hearts by replacing scar tissue with healthy heart muscle cells made from stem cells.

Get this episode:​

...

Read More

TDC is Hiring! Licensing and Commercialization Professional, KITE

November 21, 2019 /in Latest News

University Health Network (UHN) is looking for an experienced professional to fill the key role of Licensing & Commercialization Professional in our Technology Development and Commercialization Department (TDC).

Learn more, and apply here